MOMENTUM: Updated Analysis of Momelotinib vs Danazol in Symptomatic, Anemic Patients With Myelofibrosis Previously Treated With a JAKi

Source: Independent Conference Highlights of the 2022 ASH Annual Meeting*
Download Slideset
December 10-13, 2022; New Orleans, Louisiana
Updated data from the phase III MOMENTUM trial show that momelotinib maintained symptom responses, transfusion independence, and spleen responses originally achieved by Week 24 through Week 48.
Format: Microsoft PowerPoint (.ppt)
File Size: 299 KB
Released: December 12, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Amgen
Epizyme
GSK
Incyte Corporation
Jazz Pharmaceuticals
Karyopharm Therapeutics Inc.
Novartis Pharmaceuticals Corporation
Sanofi
Seagen

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings